A Dose-Ranging Study Evaluating the Safety and Efficacy of IDP-107 in Patients With Acne Vulgaris

• Status: Completed
• Trial end date: 2011-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the safety and efficacy of IDP-107 versus placebo in treating patients with acne vulgaris.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Dow Pharmaceutical Sciences

Criteria

Inclusion Criteria:

• Presence of acne vulgaris on the face and neck/trunk

• Presence of inflammatory and non-inflammatory lesions on the face

Exclusion Criteria:

• Presence of any skin condition on the face that could interfere with clinical evaluations

• Use of any systemic antibiotics or corticosteroids within 4 weeks prior to the Baseline visit

• Use of any systemic retinoids, such as isotretinoin, within 3 months prior to the Baseline visit

• Woman who is pregnant, nursing an infant, or planning a pregnancy during the study period